Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Frontage Labs Completes US Phase I Trial for China TCM Company

publication date: Feb 1, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Frontage Laboratories announced its US facility has finished a Phase I dose-escalation trial of a botanical drug for a China client. The test will be used to support a request for FDA approval of the drug. One year ago, Frontage announced a $50 million strategic collaboration with Yabao Pharma of Beijing. The two companies planned to develop sustained release delivery for more than 20 drug products for use in the US and Europe. This drug being tested may be part of that deal. More details....

Stock Symbol: (SHA: 600351)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...